GSK names McNamara as CEO of consumer health spinoutGlaxoSmithKline has said that Brian McNamara – currently head of its three-year-old consumer health joint venture with Pfizer Share XGSK names McNamara as CEO of consumer health spinouthttps://pharmaphorum.com/news/gsk-names-mcnamara-as-ceo-of-consumer-health-spinout/
Biogen bites back at critics of Aduhelm after drug’s slow startBiogen has reported $2m in sales for newly-launched Alzheimer’s therapy Aduhelm that came in below its expectations, prompting Share XBiogen bites back at critics of Aduhelm after drug’s slow starthttps://pharmaphorum.com/news/biogen-bites-back-at-critics-of-aduhelm-after-drugs-slow-start/
Study finds jabs cut severe variant COVID disease after one shotA real-world study carried out in Canada has found that COVID-19 vaccines from AstraZeneca, Pfizer/BioNTech and Moderna reduce Share XStudy finds jabs cut severe variant COVID disease after one shothttps://pharmaphorum.com/news/study-finds-jabs-cut-severe-variant-covid-disease-after-one-shot/
Happify launches Ensemble DTx for depression, anxiety in USHappify Health has launched a prescription digital therapeutic (DTx) – called Ensemble – that can assist the treatment Share XHappify launches Ensemble DTx for depression, anxiety in UShttps://pharmaphorum.com/news/happify-launches-ensemble-dtx-for-depression-anxiety-in-us/
Pfizer puts up $1bn to buy into Arvinas breast cancer programmePfizer has pledged a whopping $1 billion upfront for rights to an Arvinas drug for breast cancer from Share XPfizer puts up $1bn to buy into Arvinas breast cancer programmehttps://pharmaphorum.com/news/pfizer-puts-up-1bn-to-buy-into-arvinas-breast-cancer-programme/
NHS sets aside £340m for new Innovative Medicines FundNHS England has matched its financial backing of the Cancer Drugs Fund (CDF) with an equivalent pot of Share XNHS sets aside £340m for new Innovative Medicines Fundhttps://pharmaphorum.com/news/nhs-sets-aside-340m-for-new-innovative-medicines-fund/
Roche ‘talking to FDA’ as Alzheimer’s drug moves towards 2022 readoutPhase 3 results with Roche’s amyloid-targeting Alzheimer’s drug gantenerumab may not be due until the second half of Share XRoche ‘talking to FDA’ as Alzheimer’s drug moves towards 2022 readouthttps://pharmaphorum.com/news/roche-talking-to-fda-as-alzheimers-drug-moves-towards-2022-readout/
NICE changes its mind on rare bile duct cancer drug from IncyteIncyte’s Pemazyre has become the first targeted therapy available for NHS patients with cholangiocarcinoma or bile duct cancer, Share XNICE changes its mind on rare bile duct cancer drug from Incytehttps://pharmaphorum.com/news/nice-changes-its-mind-on-rare-bile-duct-cancer-drug-from-incyte/
Digital mental health specialist Woebot raises $90mInvestments in digital health firms are running high at the moment, and a $90 million round for four-year-old Share XDigital mental health specialist Woebot raises $90mhttps://pharmaphorum.com/news/digital-mental-health-specialist-woebot-raises-90m/
